News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

7,498 Results

Type

Article (1650)
Company Profile (2)
Press Release (5846)

Section

Business (2379)
Career Advice (54)
Deals (505)
Drug Delivery (12)
Drug Development (1491)
Employer Resources (15)
FDA (268)
Job Trends (466)
News (4381)
Policy (489)

Tag

Date

Today (3)
Last 7 days (16)
Last 30 days (66)
Last 365 days (726)
2025 (86)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)

Location

Africa (25)
Asia (399)
Australia (46)
California (96)
Canada (19)
Connecticut (5)
Europe (1227)
Illinois (57)
Japan (5)
Maryland (6)
Massachusetts (49)
New Jersey (18)
New York (12)
North Carolina (5)
Northern California (35)
Pennsylvania (9)
South America (27)
Southern California (53)
Texas (5)

Filters

Type

Article (1650)
Company Profile (2)
Press Release (5846)

Section

Business (2379)
Career Advice (54)
Deals (505)
Drug Delivery (12)
Drug Development (1491)
Employer Resources (15)
FDA (268)
Job Trends (466)
News (4381)
Policy (489)

Tag

Date

Today (3)
Last 7 days (16)
Last 30 days (66)
Last 365 days (726)
2025 (86)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)

Location

Africa (25)
Asia (399)
Australia (46)
California (96)
Canada (19)
Connecticut (5)
Europe (1227)
Illinois (57)
Japan (5)
Maryland (6)
Massachusetts (49)
New Jersey (18)
New York (12)
North Carolina (5)
Northern California (35)
Pennsylvania (9)
South America (27)
Southern California (53)
Texas (5)

7,498 Results for "abbvie".

Sort By

Earnings

AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.

February 3, 2025
·
4 min read
·
Annalee Armstrong
Neuropsychiatric disorders

AbbVie Absorbs $3.5B Cost of Schizophrenia Flop

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.

January 13, 2025
·
2 min read
·
Tristan Manalac
Infectious disease

AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.

February 10, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings

AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.

January 31, 2025
·
3 min read
·
Annalee Armstrong
Pipeline

JPM25 Day 3: AbbVie, Gilead, GSK and Dyne

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.

January 16, 2025
·
3 min read
·
Tristan Manalac
ALS

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.

January 10, 2025
·
5 min read
·
Heather McKenzie
Editorial

AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’

November 18, 2024
·
5 min read
·
Heather McKenzie
Parkinson’s disease

A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.

December 9, 2024
·
1 min read
·
Annalee Armstrong
Schizophrenia

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.

November 11, 2024
·
4 min read
·
Annalee Armstrong
Earnings

AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.

October 31, 2024
·
2 min read
·
Tristan Manalac

1 of 750

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin